188 related articles for article (PubMed ID: 20660987)
1. Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene.
Soga M; Hashimoto S; Kishimoto Y; Hirasawa T; Makino S; Inagaki S
Exp Anim; 2010; 59(4):407-19. PubMed ID: 20660987
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver.
Soga M; Kishimoto Y; Kawamura Y; Inagaki S; Makino S; Saibara T
Cancer Lett; 2003 Jun; 196(1):43-8. PubMed ID: 12860288
[TBL] [Abstract][Full Text] [Related]
3. Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model.
Sugihara T; Koda M; Kishina M; Kato J; Tokunaga S; Matono T; Ueki M; Murawaki Y
Hepatol Res; 2013 May; 43(5):547-56. PubMed ID: 23057725
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice.
Xu J; Kulkarni SR; Donepudi AC; More VR; Slitt AL
Diabetes; 2012 Dec; 61(12):3208-18. PubMed ID: 22936178
[TBL] [Abstract][Full Text] [Related]
5. The FLS mouse: a new inbred strain with spontaneous fatty liver.
Soga M; Kishimoto Y; kawaguchi J; Nakai Y; Kawamura Y; Inagaki S; Katoh K; Oohara T; Makino S; Oshima I
Lab Anim Sci; 1999 Jun; 49(3):269-75. PubMed ID: 10403441
[TBL] [Abstract][Full Text] [Related]
6. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice.
Yahagi N; Shimano H; Hasty AH; Matsuzaka T; Ide T; Yoshikawa T; Amemiya-Kudo M; Tomita S; Okazaki H; Tamura Y; Iizuka Y; Ohashi K; Osuga J; Harada K; Gotoda T; Nagai R; Ishibashi S; Yamada N
J Biol Chem; 2002 May; 277(22):19353-7. PubMed ID: 11923308
[TBL] [Abstract][Full Text] [Related]
7. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
8. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis.
Semba T; Nishimura M; Nishimura S; Ohara O; Ishige T; Ohno S; Nonaka K; Sogawa K; Satoh M; Sawai S; Matsushita K; Imazeki F; Yokosuka O; Nomura F
BMC Gastroenterol; 2013 Jul; 13():120. PubMed ID: 23875831
[TBL] [Abstract][Full Text] [Related]
9. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
11. High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice.
Iwai S; Murai T; Makino S; Min W; Morimura K; Mori S; Hagihara A; Seki S; Fukushima S
Cancer Lett; 2007 Feb; 246(1-2):115-21. PubMed ID: 16569478
[TBL] [Abstract][Full Text] [Related]
12. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
[TBL] [Abstract][Full Text] [Related]
13. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
14. Absence of adipose differentiation related protein upregulates hepatic VLDL secretion, relieves hepatosteatosis, and improves whole body insulin resistance in leptin-deficient mice.
Chang BH; Li L; Saha P; Chan L
J Lipid Res; 2010 Aug; 51(8):2132-42. PubMed ID: 20424269
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways involved in the improvement of non-alcoholic fatty liver disease.
Paz-Filho G; Mastronardi CA; Parker BJ; Khan A; Inserra A; Matthaei KI; Ehrhart-Bornstein M; Bornstein S; Wong ML; Licinio J
J Mol Endocrinol; 2013; 51(1):167-79. PubMed ID: 23718963
[TBL] [Abstract][Full Text] [Related]
16. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
17. Generation of leptin-deficient Lepmkyo/Lepmkyo rats and identification of leptin-responsive genes in the liver.
Aizawa-Abe M; Ebihara K; Ebihara C; Mashimo T; Takizawa A; Tomita T; Kusakabe T; Yamamoto Y; Aotani D; Yamamoto-Kataoka S; Sakai T; Hosoda K; Serikawa T; Nakao K
Physiol Genomics; 2013 Sep; 45(17):786-93. PubMed ID: 23800849
[TBL] [Abstract][Full Text] [Related]
18. Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis.
Rhee SD; Kim CH; Park JS; Jung WH; Park SB; Kim HY; Bae GH; Kim TJ; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):9-18. PubMed ID: 22742899
[TBL] [Abstract][Full Text] [Related]
19. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance.
Nakamura A; Tajima K; Zolzaya K; Sato K; Inoue R; Yoneda M; Fujita K; Nozaki Y; Kubota KC; Haga H; Kubota N; Nagashima Y; Nakajima A; Maeda S; Kadowaki T; Terauchi Y
Diabetologia; 2012 Dec; 55(12):3382-91. PubMed ID: 22955994
[TBL] [Abstract][Full Text] [Related]
20. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
